About Cinfa Biotech
Cinfa Biotech is a Healthcare company based in Navarres (Spain) founded in 2013, and was acquired by Mundipharma in October 2018. Biosimilars for oncology and inflammatory diseases are developed in Spain. Cinfa Biotech has raised $92.99 million across 1 funding round from investors including Mundipharma and Infarco. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Blood Cancer.
Company details
Cinfa Biotech was established in 2013 in Navarres, Spain, as a clinical-stage biotechnology firm. Biosimilars are developed by the company for oncology and inflammatory disease indications. The lead product, B12019, serves as a biosimilar to Neulasta (pegfilgrastim) for chemotherapy-induced neutropenia treatment. This candidate is presently undergoing the second phase of bioequivalence trials, with operations centered on advancing these therapies through clinical development.
- Headquarters Navarres, Spain
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cinfabiotech.com
- Acquired by Mundipharma (Oct 2018)
- Total Equity Funding$92.99M (USD)
in 1 rounds
- Latest Funding Round$92.99M (USD), Private Equity Round
Jun 2013
- InvestorsMundipharma
& 1 more
- Acquired byMundipharma
(Oct 2018)
Funding Insights of Cinfa Biotech
Cinfa Biotech has successfully raised a total of $92.99M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $92.99 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92.99M
- Total Rounds 1
- Last Round Private Equity Round — $92.99M
- First Round $92.99M
(Jun 2013)
- Investors Count 1
All 1 funding rounds of Cinfa Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2013 | $92.99M | Private Equity Round | – | – |
2 investors in total: 2 institutional.
Investors in Cinfa Biotech
Cinfa Biotech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Mundipharma and Infarco.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Conducts R&D and manufactures drugs for multiple therapeutic areas. | 1964 | infarco.com | Navarres, Spain | |
Therapeutics for oncology, rheumatoid arthritis, and respiratory conditions are developed. | 1993 | mundipharma.com | London, United Kingdom |
Investor details for Cinfa Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cinfa Biotech
3 dated milestones of Cinfa Biotech across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Cinfa Biotech is founded.
- Funding First funding round of $93.0M.
- Exit Acquired by Mundipharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cinfa Biotech
Complete news archive for Cinfa Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cinfa Biotech
Cinfa Biotech was founded in 2013.
Cinfa Biotech is headquartered in Navarres, Spain. It is registered at Navarres, Valencian Community, Spain.
Cinfa Biotech is a funded company, having raised a total of $92.99M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $92.99M, raised on Jun 2013.
Cinfa Biotech was established in 2013 in Navarres, Spain, as a clinical-stage biotechnology firm. Biosimilars are developed by the company for oncology and inflammatory disease indications. The lead product, B12019, serves as a biosimilar to Neulasta (pegfilgrastim) for chemotherapy-induced neutropenia treatment. This candidate is presently undergoing the second phase of bioequivalence trials, with operations centered on advancing these therapies through clinical development.
Cinfa Biotech has 2 investors. Key investors include Mundipharma, and Infarco.
Yes. Cinfa Biotech was acquired by Mundipharma in October 2018.